These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 9437229

  • 1. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, Deghenghi R, Bartolotta E, Ghigo E.
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [Abstract] [Full Text] [Related]

  • 2. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Peptides; 1997 Dec; 18(6):885-91. PubMed ID: 9285939
    [Abstract] [Full Text] [Related]

  • 3. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
    Arvat E, Maccagno B, Ramunni J, Di Vito L, Broglio F, Deghenghi R, Camanni F, Ghigo E.
    Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
    [Abstract] [Full Text] [Related]

  • 4. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [Abstract] [Full Text] [Related]

  • 5. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [Abstract] [Full Text] [Related]

  • 6. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
    Arvat E, Maccagno B, Ramunni J, Di Vito L, Gianotti L, Broglio F, Benso A, Deghenghi R, Camanni F, Ghigo E.
    Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
    [Abstract] [Full Text] [Related]

  • 7. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
    Arvat E, Maccagno B, Ramunni J, Broglio F, Lanfranco F, Giordano R, Benso A, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
    [Abstract] [Full Text] [Related]

  • 8. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 9. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
    Arvat E, Di Vito L, Lanfranco F, Broglio F, Giordano R, Benso A, Muccioli GP, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
    [Abstract] [Full Text] [Related]

  • 10. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 11. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
    Arvat E, Ramunni J, Giordano R, Maccagno B, Broglio F, Benso A, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
    [Abstract] [Full Text] [Related]

  • 12. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 13. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [Abstract] [Full Text] [Related]

  • 14. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E, Ramunni J, Maccagno B, Giordano R, Broglio F, Deghenghi R, Boscaro M, Ghigo E.
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [Abstract] [Full Text] [Related]

  • 15. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E, Gianotti L, Broglio F, Maccagno B, Bertagna A, Deghenghi R, Camanni F, Ghigo E.
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [Abstract] [Full Text] [Related]

  • 16. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
    Grottoli S, Arvat E, Gauna C, Maccagno B, Ramunni J, Giordano R, Maccario M, Deghenghi R, Ghigo E.
    Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
    [Abstract] [Full Text] [Related]

  • 17. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F.
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [Abstract] [Full Text] [Related]

  • 18. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
    Arvat E, Maccagno B, Ramunni J, Giordano R, Broglio F, Gianotti L, Maccario M, Camanni F, Ghigo E.
    Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
    [Abstract] [Full Text] [Related]

  • 19. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M, Veldhuis JD, Broglio F, Vito LD, Arvat E, Deghenghi R, Ghigo E.
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [Abstract] [Full Text] [Related]

  • 20. Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.
    Broglio F, Benso A, Gottero C, Muccioli G, Deghenghi R, Ghigo E, Arvat E.
    Eur J Endocrinol; 2000 Sep; 143(3):419-25. PubMed ID: 11022186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.